KNP 101
Alternative Names: IL-12-Anti-Target A; KNP-101Latest Information Update: 27 Apr 2026
At a glance
- Originator Kanaph Therapeutics
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 12 replacements; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 27 Apr 2026 Preclinical development in Solid-tumours is ongoing in South Korea (Parenteral) (Kanaph Therapeutics pipeline, April 2026)
- 25 Apr 2025 Pharmacodynamics and adverse events data from a preclinical trial in Cancer was presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Solid-tumours in South Korea (Parenteral)